Head-to-head · free
NeoGenomics, Inc. vs Nektar Therapeutics
NEO vs NKTR — return on capital, cash generation, margins and balance sheet side by side.
NEO
5 / 6
measures where NEO leads
NKTR
1 / 6
measures where NKTR leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | NEO · FY2025 | NKTR · FY2025 |
|---|---|---|
| Revenue | — | $55.2M |
| Net income | (108.0M) | (164.1M) |
| Revenue growth (yearly, multi-year) | — | 23.6% |
| Free cash flow | (21.8M) | (208.7M) |
| Free cash flow margin | — | -377.8% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -12.4% | -217.9% |
| Gross margin | 43.2% | 100.0% |
| Operating margin | -12.1% | -236.8% |
| Net debt / EBITDA | -3.79x | 0.11x |
Figures are as reported by each company; latest fiscal year shown.
Where NeoGenomics, Inc.'s cash went (FY2025)
- Capital spending
- $27.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Nektar Therapeutics's cash went (FY2025)
- Capital spending
- $171000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free